Physicians' Academy for Cardiovascular Education

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017

How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##SCROLLER_ITEMS_FULL_TITLE##

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon

GLP-1 RA demonstrates superiority in reduction of CV events in T2DM

News - Nov. 7, 2018

The REWIND study met its primary efficacy endpoint, showing that administration of the GLP-1 RA dulaglutide once-weekly significantly reduces MACE versus placebo in adult diabetic patients with or without CVD.

BP regulation appears central to CV benefit seen with improved glycemic control

Literature - Oct. 25, 2018 - Schwarz PEH et al. - J Am Coll Cardiol 2018

This umbrella review of recent systematic reviews and meta-analyses compared the effectiveness and underlying mechanisms of various prevention and treatment strategies to regulate blood glucose.

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom
In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.

In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.

GLP-1 receptor agonist therapy associated with decreased CV risk in T2DM patients with CKD

Literature - Oct. 17, 2018 - Mann JFE et al. - Circulation 2018
In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.

In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.

Preventing cardiovascular disease in patients with T2DM: How to apply novel outcome data with GLP-1 RA to clinical practice

CME accredited E-Learning

Online-CME - Online-CME - This course consists of 3 separate lectures
Online-CME - This course consists of 3 separate lectures

CME accredited course focussed on the role of GLP-1 agonists in preventing cardiovascular disease in patients with T2DM. Member registration (free) is needed to enroll in this course

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany
Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Summary | GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

August 27, 2018 – Dr. Filip K. Knop, MD, PhD

This is a summary of the presentation by dr. Filip K. Knop, in which he explains that GLP-1RA treatment has also beneficial effects beyond glucose metabolism in T2DM patients.

Glucagon-like peptide-1 analogue promotes weight loss in obese, non-diabetic individuals

Literature - Sep. 12, 2018 - O’Neil PM et al. - The Lancet 2018
In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.

In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.

Novel concepts and treatments of comorbidities in heart failure with preserved ejection fraction

CME accredited E-Learning

Online-CME - Online-CME - This course consists of 3 separate lectures
Online-CME - This course consists of 3 separate lectures

CME accredited course focussed on novel concepts and treatments of comorbidities in heart failure with preserved ejection fractions. Member registration (free) is needed to enroll in this course

Slides: GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

Presentation Prof. Filip K Knop

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - Filip K Knop, MD – Copenhagen, Denmark
This lecture by prof. Filip K Knop was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Diabetes & CVD: Time for a multifactorial approach

Presentation Prof. John Deanfield

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - John Deanfield, MD - London, UK
This lecture by prof. John Deanfield was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD